Melqart Asset Management (UK) portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Melqart Asset Management (UK) reported a $1.1 bn portfolio of 40 positions to the SEC as of the end of Q2 2026. Its largest positions are WBD, TXNM, NSC. During the quarter it opened Abivax and exited Kenvue and Fabrinet.
Sections with a free account
What changed this quarter
53 positions with a change (14 new, 11 added to, 15 trimmed, 13 sold); also, 2 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Warner Bros. Discovery+126%more sharesIncreased5.5% → 11.6%
- Kenvue−4.1 ppof portfolioSold out4.3% → —
- Abivax+3.9 ppof portfolioNew— → 3.9%
- Taiwan Semiconductor Manufacturing−63%fewer sharesReduced3.9% → 1.9%
- Penumbra+127%more sharesIncreased2.6% → 5.6%
- Sandisk−88%fewer sharesReduced3.1% → 1.3%
- Revolution Medicines−55%fewer sharesReduced2.6% → 2.2%
- Norfolk Southern+51%more sharesIncreased4.6% → 7.3%
- NVIDIA−49%fewer sharesReduced4.2% → 2.4%
- Marvell Technology−81%fewer sharesReduced2.3% → 1.3%
- Fabrinet−2.2 ppof portfolioSold out2.3% → —
- Broadcom−2.1 ppof portfolioSold out2.2% → —
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Warner Bros. DiscoveryWBD11.6%
- TXNM EnergyTXNM7.4%
- Norfolk SouthernNSC7.3%
- Electronic ArtsEA7.0%
- CytokineticsCYTK6.2%
- PenumbraPEN5.6%
- Chart Industries4.3%
- AbivaxABVX3.9%
- Global PaymentsGPN3.7%
- AESAES2.9%
- Advanced Micro DevicesAMD2.6%
- ASML HoldingASML2.4%
- NVIDIANVDA2.4%
- Indivior PharmaceuticalsINDV2.3%
- Revolution MedicinesRVMD2.2%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 23%
- ● Communication Services 19%
- ● Information Technology 19%
- ● Industrials 13%
- ● Utilities 10%
- ● Consumer Discretionary 7%
- ● Financials 5%
- ● Real Estate 1%
- ● No sector 1%
- ● Materials 1%
- ● SPAC / vehículos 1%
How its portfolio changed (8 quarters)
Q2 2026: 40
Q2 2026: 60%
Q2 2026: 37.7%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Feb 25, 2026 (high confidence).
The data, as reported: MELQART ASSET MANAGEMENT (UK) LTD (CRD 287888): 7.B private funds: 2 hedge (gross assets $2.4 bn); 5.D assets by client type: pooled vehicles 88%, corporations 12% (of $2.9 bn)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Broad Bay Capital ManagementInvestment firm · $1.1 bn
- Wolf Hill Capital ManagementInvestment firm · $1.0 bn
- Ironvine Capital PartnersInvestment firm · $1.1 bn
- Engine Capital ManagementInvestment firm · $1.0 bn
- Apis Capital AdvisorsInvestment firm · $1.0 bn
- Hook Mill Capital PartnersInvestment firm · $1.1 bn